# NCT05347134 (NCT05347134)

> SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05347134
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Triple Negative Breast Cancer
- Interventions: SKB264
- Enrollment: 254
- Primary outcome: Progression-free survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05347134